Table 1.

The haemolytic activity of compounds studied and the predominated human RBC shape after the standard incubation with compounds (1 h, 37° C).

Compound	Haemolytic Activity (%) at 0.1 mg/mL	Dominate cells shape at 0.1 mg/mL	Haemolytic activity (%) at 0.025 mg/mL	Dominate cells shape at 0.025 mg/mL	Intensity of MC540 at 0.1 mg/mL
Control (0 mg/mL)	2.21 ± 0.57	D	2.14 ± 0.68	D	1.0
1	2.92 ± 0.68	D	2.53 ± 0.47	D	1.14
2	3.27 ± 0.19	D	1.08 ± 0.81	D	1.08
3	8.41 ± 1.51	D	3.78 ± 1.08	D	1.22
4	8.16 ± 1.76	D/E	3.02 ± 0.44	D	NA
5	12.08 ± 2.41	D	2.85 ± 0.52	D	NA
6	5.87 ± 1.25	D	2.91 ± 1.15	DE	1.12
7	8.43 ± 1.17	S	3.05 ± 0.96	S/DE	1.54
8	8.69 ± 2.35	S	2.47 ± 1.04	DE	1.71
9	4.78 ± 1.66	S	2.09 ± 1.22	D/S	1.43
10	10.77 ± 3.42	SS	3.06 ± 0.55	D/S	NA
11	74.12 ± 8.62	SS/S	3.43 ± 0.51	D/DE	NA
12	18.93 ± 4.47	D/S	3.07 ± 0.48	DE	NA
13	3.08 ± 0.29	D	2.59 ± 0.26	D	1.16
14	3.84 ± 1.33	D	2.14 ± 0.54	D	0.91
15	9.82 ± 2.41	DS	2.52 ± 0.73	D	NA

The predominant human RBC shape: D-biconcave-discocytes, control cells, DE-discoechinocytes; E-echinocytes; S-stomatocytes; SS-spherostomatocytes. Haemolytic activity > 5% means the significant membrane-perturbing activity of a compound. NA not analyzed because of haemolysis. Data represent the mean value ± SD from 3 independent experiments (n = 9).